CAP-Ketamine for Antidepressant Resistant PTSD

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
PTSDPosttraumatic Stress Disorder
Interventions
DRUG

Ketamine

FDA approved anesthetic medication with rapid acting antidepressant effects.

DRUG

Placebo/Saline

This is a saline placebo/non-active solution.

Trial Locations (3)

55417

Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis

78234

Brooke Army Medical Center, San Antonio

06516

VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven

All Listed Sponsors
collaborator

The University of Texas Health Science Center at San Antonio

OTHER

collaborator

Brooke Army Medical Center

FED

collaborator

Minneapolis Veterans Affairs Medical Center

FED

lead

VA Office of Research and Development

FED

NCT02655692 - CAP-Ketamine for Antidepressant Resistant PTSD | Biotech Hunter | Biotech Hunter